Replies to post #20196 on Ayala Pharmaceuticals Inc (ADXS)

[ignatiusrielly35]

Hovacre, isn't that because blood cancers are much easier to treat? Less defenses than solid tumors.

[huskercatman123]

Hi Hovacre,

Will this approach be comparable to CAR-T, as far as somewhat similar targets?

http://ir.advaxis.com/press-releases/detail/1256/advaxis-and-sellas-announce-licensing-agreement-for

Thanks

[Bourbon_on_my_cornflakes]

the ADXS approach is comparable to Car-T in that both are seeking to raise T-cell activity...so in the macro sense they are quite comparable. yes the method is different....ours is safer and costs far less....but if Car-t Comapnies have $2-3 billion valuations, so should ADXS. I think long run ADXS will be the frontline therapy and car-t only a backup...and that has big implications for market cap as well. And unlike Car-T we havent killed anyone with ours.